Consolidated cash flow statements - USD ($)
$ in Millions |
3 Months Ended |
6 Months Ended |
Jun. 30, 2020 |
Jun. 30, 2019 |
Jun. 30, 2020 |
Jun. 30, 2019 |
| Statement [line items] |
|
|
|
|
| Net income from continuing operations |
$ 1,867
|
$ 2,109
|
$ 4,040
|
$ 3,977
|
| Reversal of non-cash items and other adjustments |
2,345
|
2,085
|
5,202
|
4,101
|
| Dividends received from associated companies and others |
2
|
3
|
489
|
463
|
| Interest received |
5
|
55
|
37
|
140
|
| Interest paid |
(227)
|
(239)
|
(321)
|
(406)
|
| Other financial receipts |
52
|
10
|
261
|
10
|
| Other financial payments |
(10)
|
28
|
(19)
|
(16)
|
| Taxes paid |
(303)
|
(560)
|
(899)
|
(960)
|
| Net cash flows from operating activities from continuing operations before working capital and provision changes |
3,731
|
3,491
|
8,790
|
7,309
|
| Payments out of provisions and other net cash movements in non-current liabilities |
(420)
|
(323)
|
(824)
|
(516)
|
| Change in net current assets and other operating cash flow items |
650
|
(57)
|
(1,477)
|
(1,348)
|
| Net cash flows from operating activities from continuing operations |
3,961
|
3,111
|
6,489
|
5,445
|
| Net cash flows from operating activities from discontinued operations |
|
|
|
78
|
| Total net cash flows from operating activities |
3,961
|
3,111
|
6,489
|
5,523
|
| Purchases of property, plant and equipment |
(238)
|
(279)
|
(475)
|
(561)
|
| Proceeds from sale of property, plant and equipment |
1
|
648
|
4
|
812
|
| Purchases of intangible assets |
(214)
|
(161)
|
(460)
|
(498)
|
| Proceeds from sale of intangible assets |
49
|
210
|
105
|
281
|
| Purchases of financial assets |
(38)
|
(45)
|
(90)
|
(154)
|
| Proceeds from sale of financial assets |
117
|
142
|
359
|
177
|
| Purchases of other non-current assets |
(7)
|
(14)
|
(48)
|
(24)
|
| Proceeds from sale of other non-current assets |
|
|
0
|
3
|
| Acquisitions and divestments of interests in associated companies, net |
(2)
|
(1)
|
(4)
|
(3)
|
| Acquisitions and divestments of businesses, net |
0
|
(286)
|
(9,901)
|
(382)
|
| Purchases of marketable securities and commodities |
(74)
|
(75)
|
(345)
|
(120)
|
| Proceeds from sale of marketable securities and commodities |
72
|
69
|
394
|
2,428
|
| Net cash flows used in/from investing activities from continuing operations |
(334)
|
208
|
(10,461)
|
1,959
|
| Net cash flows used in investing activities from discontinued operations |
(91)
|
(682)
|
(105)
|
(1,105)
|
| Total net cash flows used in/from investing activities |
(425)
|
(474)
|
(10,566)
|
854
|
| Dividends paid to shareholders of Novartis AG |
|
|
(6,987)
|
(6,645)
|
| Acquisitions of treasury shares |
(9)
|
(2,368)
|
(150)
|
(2,590)
|
| Proceeds from exercised options and other treasury share transactions |
30
|
|
846
|
200
|
| Increase in non-current financial debts |
|
|
4,945
|
|
| Repayment of non-current financial debts |
(1,002)
|
(7)
|
(2,002)
|
(3,008)
|
| Change in current financial debts |
(1,169)
|
(793)
|
2,486
|
(942)
|
| Payment of lease liabilities, net |
(74)
|
(69)
|
(142)
|
(91)
|
| Impact of change in ownership of consolidated entities |
|
(5)
|
|
(5)
|
| Other financing cash flows, net |
52
|
532
|
(142)
|
71
|
| Net cash flows used in financing activities from continuing operations |
(2,172)
|
(2,710)
|
(1,146)
|
(13,010)
|
| Net cash flows used in/from financing activities from discontinued operations |
(13)
|
2,682
|
(26)
|
3,299
|
| Total net cash flows used in financing activities |
(2,185)
|
(28)
|
(1,172)
|
(9,711)
|
| Net change in cash and cash equivalents before effect of exchange rate changes |
1,351
|
2,609
|
(5,249)
|
(3,334)
|
| Cash and cash equivalents of discontinued operations at end of prior period |
|
499
|
|
|
| Effect of exchange rate changes on cash and cash equivalents |
38
|
76
|
54
|
54
|
| Total net change in cash and cash equivalents |
1,389
|
3,184
|
(5,195)
|
(3,280)
|
| Cash and cash equivalents at beginning of period |
4,528
|
6,807
|
11,112
|
13,271
|
| Cash and cash equivalents at end of period |
$ 5,917
|
$ 9,991
|
$ 5,917
|
$ 9,991
|